Introduction {#s1}
============

Venous thromboembolism (VTE) is a serious and potentially life-threatening condition. Manifestations of VTE include deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is associated with high morbidity and mortality. Considerable amounts of money are also spent on the treatment of VTE in the developed countries of Europe and North America. VTE affects approximately 1.0--1.8 people per 1,000 annually ([@B1], [@B2]). The incidence rises exponentially with age, and the risk significantly increases in people over the age of 40 years ([@B3]). Multiple risk factors are involved in the development of VTE. VTE risk factors can be divided into physiological and pathophysiological, clinical and laboratory, and congenital and acquired factors ([**Table 1**](#T1){ref-type="table"}) ([@B1], [@B2], [@B4]).

###### 

Risk factors for VTE \[adapted from Refs. ([@B1], [@B2], [@B4])\].

  --------------------------------- -------------------------
  Congenital                        Antithrombin deficiency
  Protein C deficiency              
  Protein S deficiency              
  Factor V Leiden mutation          
  Factor II mutation                
  Acquired                          Increasing age
  Malignancy                        
  Antiphospholipid syndrome         
  Inflammatory bowel disease        
  Systemic lupus erythematosus      
  Nephrotic syndrome                
  Overweight and obesity            
  Microalbuminuria                  
  External                          Infectious disease
  Surgery, trauma, immobilization   
  Pregnancy and puerperium          
  Oral contraceptives               
  Hormonal replacement therapy      
  Antipsychotic drugs               
  Air transport (long haul)         
  Mixed                             High factor VIII levels
  APC resistance                    
  Hyperhomocysteinemia              
  High factor IX levels             
  High factor XI levels             
  Fibrinolysis abnormalities        
  Partially confirmed               High CRP levels
  Smoking                           
  Dyslipidemia                      
  Male sex                          
  --------------------------------- -------------------------

VTE, venous thromboembolism; CRP, C-Reactive Protein.

The congenital risk factors for VTE have varying clinical implications for the patient as they confer different degrees of relative risk for VTE development. The risk of thrombosis rises significantly when multiple factors occur together. In older patients, acquired risk factors occur more frequently, which explains the significantly increased incidence of VTE in the elderly population.

The pathophysiological mechanism underlying VTE formation is the development of a relative thrombophilic state. This involves a shift in the hemostatic system towards thrombosis. If a genetic disposition is prominent in the etiopathogenesis of VTE, patients are determined to have hereditary thrombophilia. If external risk factors prevail, the condition is determined to be an acquired hypercoagulable state. A hypercoagulable state may result from the presence of any of the conditions belonging to the so-called Virchow triad (venous stasis, hypercoagulability, and vessel wall damage) ([@B1], [@B2]).

In patients with a mental illness, the risk of VTE is increased for several reasons. In a previous study, we found significantly increased activation of markers of thrombogenesis (sP-selectin, D-dimer, FVIII) in untreated patients experiencing a first episode of psychosis compared to healthy volunteers ([@B5]). The markers of thrombogenesis continued to be elevated after 1 year of treatment ([@B6]). Antiphospholipid antibodies (APAs), especially anticardiolipin antibodies (ACLAs), may serve as a marker of autoimmune reactivity, or they may directly interfere with phospholipid metabolism in schizophrenia patients. They may also have prothrombogenic effects. Inflammatory markers are also elevated during acute psychosis, which may lead to an increased risk of pathological blood coagulation ([@B7]). Hyperhomocysteinemia, which is also a risk factor for VTE, can occur in patients with mental disorders who also smoke, have poor dietary habits, and consume excessive amounts of coffee

Antipsychotic medications are another risk factor for VTE in patients with a psychotic disease ([@B8]). Antipsychotic drugs contribute to the development of a hypercoagulable state through several potential mechanisms, including drug-induced sedation, obesity, hyperprolactinemia, increased platelet aggregation, and elevation of APA ([@B5], [@B9]).

According to a meta-analysis by Barbui et al. ([@B10]), exposure to antipsychotic treatment results in a 50% increased risk for VTE. In another meta-analysis, the low-potency antipsychotic agents had the highest odds of VTE (OR 2.91; 95% CI 1.81--4.71), followed by second-generation antipsychotics (OR 2.20; 95% CI 1.22--3.96) and then the traditional neuroleptics (OR 1.72; 95% CI 1.31--2.24) ([@B11]). The highest risk of VTE emerges during the first 3 months after initiation of antipsychotic treatment ([@B12]). Other studies found the highest risk in the first month after the initiation of an antipsychotic ([@B13], [@B14]). In addition to the time period following drug administration and the antipsychotic drug class used, other risk factors include using higher drug doses, using a combination of several antipsychotic drugs, and parenteral administration of antipsychotic agents ([@B15]).

Through a long-term project named ANTRE (ANTipsychotics, ThRombosis, Embolism) involving interdisciplinary cooperation within the University Hospital in Hradec Kralove, we have been aiming to develop a comprehensive approach to the issue of VTE in patients treated with antipsychotic drugs. Cases of VTE development are carefully recorded. In addition to isolated case reports of VTE development during treatment with different antipsychotic agents, we recorded 10 cases involving the administration of olanzapine.

Patients and Methods {#s2}
====================

The patient group consisted of a total of 10 patients (women n = 3) who were treated with olanzapine. VTE occurrence was monitored prospectively between 2004 and 2013 in a specialized outpatient unit for VTE treatment. The average age of the patients was 46 years, with a range of 17 to 71 years. Three patients had a diagnosis of delusional disorder, two had paranoid schizophrenia, and two had bipolar disorder. The other patient diagnoses were an addiction to multiple narcotic drugs, behavioral disorder related to pregnancy and puerperium, and mental retardation with a behavioral disorder. The duration of psychiatric illness prior to the occurrence of VTE was determined. We also determined the duration and dose of olanzapine utilized prior to VTE and recorded other psychotropic drugs taken concomitantly. Information was collected from patient-reported history, the hospital information system, and reports by attending outpatient psychiatrists. None of the patients had previously suffered from VTE. Patient history was used to determine if there was a family history (FH) of VTE. In the patient group, VTE occurred either during hospitalization or during outpatient care. VTE diagnosis and subsequent treatment were conducted by an internist. If clinical symptoms suggested VTE, then additional examinations were conducted. In all cases, VTE was verified using imaging techniques (duplex ultrasonography, CT angiography) and laboratory methods (D-dimer). Blood tests were used to detect laboratory risk factors. All laboratory tests were conducted in the same laboratory.

Due to the case study nature of the data, we mostly used methods of descriptive statistics. Frequencies for sex, clinical and laboratory risk factors, smoking, and VTE together with averages for age, weight gain, dose of olanzapine, and length of use were calculated. A paired-sample t-test was used for weight gain.

Results {#s3}
=======

VTE manifested clinically as DVT in the lower limbs in nine patients. In one of these patients, PE also developed at the same time. In one patient, VTE manifested clinically as neurological symptoms without symptoms of DVT. These atypical symptoms were due to a paradoxical embolization in the setting of a heart malformation, patent foramen ovale. Clinical or laboratory risk factors for VTE development were present in all the patients. The most frequent clinical risk factors were obesity (n = 7) and smoking (n = 6). The most frequent laboratory risk factors were elevated FVIII level (n = 4) and mild homocysteinemia (HCY) (n = 3). In these patients, mild HCY was always present together with elevated FVIII level. FV Leiden mutation was detected in two patients. Both clinical and laboratory risk factors were present in half (n = 5) of the patients. Positive FH for VTE was found in three patients. In one case, VTE resulted in the death of an affected family member. In six patients, VTE developed within 6 months of olanzapine initiation, and within 3 months in three patients. VTE developed during hospitalization in three cases. The average dose of olanzapine was 14.5 mg daily, and the average length of use was 14 months prior to VTE. Only one patient was using olanzapine monotherapy. There was also statistically significant weight gain recorded during treatment with olanzapine (p = 0.031). The results are summarized in [**Table 2**](#T2){ref-type="table"}.

###### 

Characteristics of the patient group, including demography, diagnosis, duration of illness, dose and time of olanzapine use, adjuvant medication, and BMI before olanzapine initiation and during VTE development.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
           Sex (age range)   Diagnosis (years of illness)   Psychotropic drugs   BMI before/after OLA treatment   VTE risk factors   VTE                                                                              
  -------- ----------------- ------------------------------ -------------------- -------------------------------- ------------------ -------------------- --------------------------- -------------------------- ---- ------------------------
  **1**    Male\             F22 (24)                       5 (2)                alprazolam 1                     26.4/27.6          −                    mild HCY\                   DVT\                       −    LMWH\
           (51--55)                                                                                                                                       elevated FVIII              PE                              warfarin

  **2**    Male\             F22 (0.5)                      10 (6)               sertraline 100                   23.7/23.7          smoking              FII mutation (het)          DVT                        \+   LMWH\
           (51--55)                                                                                                                                                                                                   warfarin

  **3**    Male\             F20 (10)                       10 (6)               zotepine 100\                    30/34              obesity\             FV Leiden mutation (het)    DVT                        −    LMWH\
           (36--40)                                                              levomepromazine 25                                  smoking                                                                          warfarin\
                                                                                                                                                                                                                      alteplase\
                                                                                                                                                                                                                      SCF

  **4**    Female\           F22 (32)                       20 (17)              citalopram 40\                   29.7/30.9          obesity\             mild HCY\                   DVT                        −    LMWH\
           (51--55)                                                              oxazepam 15                                         smoking\             elevated FVIII                                              warfarin
                                                                                                                                     immobilization                                                                   

  **5**    Female\           F31 (19)                       20 (6)               escitalopram 10\                 29.8/30.8          obesity\             −                           DVT                        \+   LMWH\
           (71--75)                                                              trazodone 150\                                      LE varicose veins\                                                               warfarin
                                                                                 oxazepam 15\                                        immobilization                                                                   
                                                                                 lamotrigine 25                                                                                                                       

  **6**    Male\             F19.2 (10)                     10 (12)              clonazepam 5\                    30.9/30            obesity\             −                           DVT                        −    LMWH\
           (56--60)                                                              promethazine 50                                     smoking                                                                          warfarin

  **7**    Female\           F53.1 (0.2)                    20 (0.17)            venlafaxine 225                  28.2/32.6          obesity\             −                           DVT                        \+   LMWH\
           (31--35)                                                                                                                  immobilization\                                                                  warfarin
                                                                                                                                     puerperium                                                                       

  **8**    Male\             F20 (13)                       30 (84)              clonazepam 1                     28/28.6            smoking              elevated FVIII              DVT                        −    warfarin
           (36--40)                                                                                                                                                                                                   

  **9**    Male\             F72.1 (17)                     10 (1)               levomepromazine 125\             25.2/31.7          obesity              FV Leiden mutation (het)\   DVT                        −    LMWH\
           (15--19)                                                              chlorprothixene 250\                                                     elevated FVIII\                                             warfarin
                                                                                                                                                          mild HCY                                                    

  **10**   Male\             F30.2 (0.7)                    10 (3.5)             −                                31.7/30.5          obesity\             −                           paradoxical embolization   −    ac. acetylsalicylicum\
           (41--45)                                                                                                                  smoking\                                                                         occluder implantation
                                                                                                                                     LE varicose veins                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OLA, olanzapine; BMI, body mass index; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; iCVA, ischemic cerebrovascular accident; LE, lower extremities; HCY, homocysteinemia; het, heterozygote; PH, personal history; FH, family history; LWMH, low-molecular-weight heparin; SCF, subrenal cava filter.

Discussion {#s4}
==========

Olanzapine is a widely used, affordable, and effective second-generation antipsychotic drug. It is indicated for the treatment of schizophrenia and bipolar disorder. In clinical practice, the spectrum of its use is much wider. Off-label indications include psychotic disorders of various etiologies (toxic and organic), behavioral disorders in patients with dementia, eating disorders, and personality disorders. The relatively high incidence of olanzapine-related VTE may be distorted by the high number of patients treated with this antipsychotic agent.

A possible prothrombogenic mechanism of olanzapine at the molecular level is an affinity for 5-HT~2A~ serotonin receptors. Blocking these receptors results in increased platelet aggregation and increased blood coagulability ([@B16]). Blockade of α~1~ adrenergic receptors by olanzapine may cause hypotension and thereby venous stasis in the lower limbs. Another mechanism may be olanzapine-induced production of the antiphospholipid antibodies: lupus anticoagulant (LA) and ACLAs ([@B17]). Increasing these APA titers is associated with a prothrombogenic state ([@B18]). Olanzapine may also induce a temporary increase in prolactin levels early in the course of treatment. Hyperprolactinemia correlates with increased levels of P-selectin, a platelet activation marker ([@B19]).

Metabolic symptoms caused by olanzapine represent an indirect mechanism for VTE development. The prothrombogenic metabolic symptoms that often occur during olanzapine treatment include hyperglycemia, hyperleptinemia, dyslipidemia, and weight gain ([@B20]). Weight gain is mainly due to the blockade of H~1~ histamine and 5-HT~2C~ serotonin receptors by olanzapine.

Obesity \[body mass index (BMI) ≥ 30)\] is associated with an up to two-fold increase in the risk of VTE development. Obese patients have reduced fibrinolytic activity and capacity. Higher levels of the procoagulation factors FVIII and FIX also occur ([@B21]). Central obesity is also accompanied by a procoagulant and hypofibrinolytic state related to inflammation, oxidative stress, dyslipidemia, and ectopic fat deposition ([@B22]). In our group, obesity was identified in seven patients. The patients' body weight increased significantly during olanzapine treatment.

Another indirect risk factor associated with olanzapine is sedation, which reduces physical activity, leading to a reduction in blood flow. Venous stasis, which is one of the factors from the Virchow triad, increases the risk of VTE. The level of sedation in our patients could also have been potentiated by adjuvant medication. In 50% (n = 5), benzodiazepines were administered together with olanzapine. In 20% (n = 2), the sedating antipsychotic agent levomepromazine was used with olanzapine.

The risk of VTE development increases significantly during prolonged hospitalization. Patients with a mental disorder require hospitalization frequently and repeatedly. In our group, VTE occurred during hospitalization in three patients. During hospitalization, a general reduction in physical activity occurs, and sedatives are often administered at higher doses compared to outpatient treatment. Some patients also require physical restraint. During physical restraint, such as strapping the patient to a bed, injury or compression of a limb may occur. Venostasis and vascular endothelium damage can also occur, which increases the risk for VTE ([@B23]). In our group, physical restraint was used in only one patient.

Literature reports that the risk of VTE is highest in the first 3 months after initiation of antipsychotic treatment. This finding was confirmed in 30% of patients in our group; however, in 60%, VTE developed within 6 months after olanzapine initiation. Our findings confirm those of other studies, which found that the highest risk of VTE development exists in the early stages of antipsychotic treatment ([@B24]).

FV Leiden mutation is the most frequently occurring laboratory risk factor for VTE development in the general population ([@B1]). It can be detected in 20--25% of patients with a diagnosis of VTE. This corresponds with the findings from our group, in which FV Leiden mutation was identified in 20% (n = 2) of the cases.

This is the largest group of patients with VTE occurrence during olanzapine treatment ever described in the literature. The merits of our work include meticulous VTE diagnosis using modern imaging methods and laboratory testing. The number of VTE cases reported during treatment with olanzapine may be influenced by the fact that it is a very frequently used antipsychotic drug.

Antipsychotic agents, in general, may be regarded as one risk factor for VTE development. Patients with psychosis have a higher incidence of cardiovascular risk factors (obesity, diabetes mellitus, arterial hypertension, dyslipidemia, and smoking) that are also associated with a higher risk for VTE development ([@B25]). In VTE pathogenesis, it is difficult to differentiate between the role of the underlying psychiatric condition, hospitalization or physical restraint, and the action of antipsychotic drugs. The precise biological mechanisms of increased VTE during antipsychotic use remain unclear.

When selecting particular treatment, the presence of VTE risk factors should be considered for every patient. Treatments should be selected only if they do not further increase the risk. During antipsychotic therapy, the risk for VTE development needs to be monitored, and prophylactic measures should be initiated in a timely manner. Diagnosing VTE in mentally ill patients may be more difficult than in the general population. High-risk patients treated with antipsychotic drugs should receive clear information on the possible adverse effects of the treatment, including clinical signs and symptoms of venous thrombosis and PE, and on the necessity of seeking medical attention if such symptoms occur.

In hospitalized immobilized psychiatric patients, the degree of VTE risk needs to be determined so that preventive measures can be taken ([@B26]). Whenever clinical symptoms of VTE occur, the diagnosis needs to be confirmed or ruled out immediately by imaging and laboratory tests.

Further prospective studies are needed to shed more light on the relationship between VTE and antipsychotic agents, focusing on risk quantification for the individual antipsychotic drugs, and to elucidate the basic biological mechanisms.

Conclusion {#s5}
==========

We have described 10 patients with VTE occurrence during treatment with olanzapine. In all the cases, additional clinical or laboratory risk factors were detected. Olanzapine can be considered a precipitating factor for VTE development. During olanzapine administration, patients need to be monitored for clinical signs of VTE, particularly when multiple risk factors are present.
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